{"pub": "marketwatch", "url": "https://wsj.com/articles/biogens-alzheimers-revelation-isnt-so-simple-11571757469", "downloaded_at": "2019-10-22 15:35:11.937233+00:00", "title": "Biogen\u2019s Alzheimer\u2019s Revelation Isn\u2019t So Simple", "language": "en", "text": "A stunning reversal of fortune for an experimental Alzheimer\u2019s disease drug has Biogen shares off the mat. But investors shouldn\u2019t abandon their skepticism just yet.\n\nTuesday morning was a memorable one for Biogen shareholders. The company said it now plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer\u2019s disease. This was a shock to investors, as the company had seemingly thrown in the towel on the drug after a pair phase 3 studies of the drug back in March.\n\n...", "description": "A stunning reversal of fortune for an experimental Alzheimer\u2019s disease drug has Biogen shares off the mat. But investors shouldn\u2019t abandon their skepticism just yet.", "authors": ["Charley Grant", "Charles.Grant Wsj.Com"], "top_image": "https://images.wsj.net/im-119366/social", "published_at": "2019-10-22"}